drugset / Trial / NCT01057407

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

NCT01057407

Phase 3 Completed 110 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-labeled study to examine the non-inferiority of ASP1585 to sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on hemodialysis.

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bixalomer Small molecule Oral
Comparator Sevelamer Other / unclassified Oral